Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.1.39.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.4.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.4.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.23.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.23.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DY.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DY.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.2.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LJ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LJ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LE.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LE.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
MD.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MD.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.5.1.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LE.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LE.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDQNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDQNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.502NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.502NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.7.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.7.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDK.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDK.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.4.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.4.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.37NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.37NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JQ.2.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JQ.2.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.529 (Omicron)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.529 (Omicron)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.41.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BF.41.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.39NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BF.39NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BA.2.3.20NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.33 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.33 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BE.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used